A Nature Biotechnology report described engineering an AAV‑deliverable suppressor tRNA that reads through UGA stop codons in vivo, presenting a potentially disease‑agnostic strategy for treating disorders caused by nonsense mutations. The team optimized a suppressor tRNA construct and demonstrated in vivo delivery and activity, positioning tRNA‑based approaches as an alternative to gene replacement or editing for select mutation types. The platform addresses a common class of pathogenic mutations and could simplify development by targeting the mutation mechanism rather than specific genes. Translational teams must now evaluate long‑term expression, off‑target readthrough risks, and immune responses to AAV‑encoded tRNAs in relevant large‑animal models before clinical translation.